Venous thromboembolism risk and adequacy of prophylaxis in high risk pregnancy in the Arabian Gulf

Faisal Alsayegh, Waleed Al-Jassar, Salima Wani, Muna Tahlak, Awatef Al-Bahar, Lamya Al-Kharusi, Halima Al-Tamimi, Faten El-Taher, Naeema Mahmood, Ibrahim Al-Zakwani

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: To estimate the prevalence of venous thromboembolism (VTE) risk factors in pregnancy and the proportion of pregnancies at risk of VTE that received the recommended prophylaxis according to the American College of Chest Physicians (ACCP) 2012 published guidelines in antenatal clinics in the Arabian Gulf. Methods: The evaluation of venous thromboembolism (EVE)-Risk project was a non-interventional, cross-sectional, multi-centre, multi-national study of all eligible pregnant women (≥17 years) screened during antenatal clinics from 7 centres in the Arabian Gulf countries (United Arab Emirates, Kuwait, Bahrain, Qatar and Oman). Pregnant women were recruited during a 3-month period between September and December 2012. Results: Of 4,131 screened pregnant women, 32% (n=1,337) had ≥1 risk factors for VTE. Common VTE risk factors included obesity (76%), multiparity (33%), recurrent miscarriages (9.1%), varicose veins (6.9%), thrombophilia (2.6%), immobilization (2.0%), sickle cell disease (2.8%) and previous VTE (1.6%). Only 8.3% (n=111) of the high risk patients were on the recommended VTE prophylaxis. Enoxaparin was used in 80% (n=89) of the cases followed by tinzaparin (4%; n=4). Antiplatelet agents were prescribed in 11% (n=149) of pregnant women. Of those on anticoagulants (n=111), 59% (n=66) were also co-prescribed antiplatelet agents. Side effects (mainly local bruising at the injection site) were reported in 12% (n=13) of the cases. Conclusion: A large proportion of pregnant women in the Arabian Gulf countries have ≥1 VTE risk factor with even a smaller fraction on prophylaxis. VTE risk assessment must be adopted to identify those at risk who would need VTE prophylaxis.

Original languageEnglish
Pages (from-to)368-373
Number of pages6
JournalCurrent Vascular Pharmacology
Volume14
Issue number4
Publication statusPublished - Jul 1 2016

Fingerprint

High-Risk Pregnancy
Venous Thromboembolism
Pregnant Women
Platelet Aggregation Inhibitors
Bahrain
Qatar
United Arab Emirates
Oman
Kuwait
Enoxaparin
Habitual Abortion
Pregnancy
Thrombophilia
Varicose Veins
Sickle Cell Anemia
Parity
Immobilization
Anticoagulants
Obesity
Guidelines

Keywords

  • Anticoagulation
  • Antiplatelet
  • Deep vein thrombosis
  • Middle East
  • Pregnancy
  • Venous thromboembolism

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Venous thromboembolism risk and adequacy of prophylaxis in high risk pregnancy in the Arabian Gulf. / Alsayegh, Faisal; Al-Jassar, Waleed; Wani, Salima; Tahlak, Muna; Al-Bahar, Awatef; Al-Kharusi, Lamya; Al-Tamimi, Halima; El-Taher, Faten; Mahmood, Naeema; Al-Zakwani, Ibrahim.

In: Current Vascular Pharmacology, Vol. 14, No. 4, 01.07.2016, p. 368-373.

Research output: Contribution to journalArticle

Alsayegh, F, Al-Jassar, W, Wani, S, Tahlak, M, Al-Bahar, A, Al-Kharusi, L, Al-Tamimi, H, El-Taher, F, Mahmood, N & Al-Zakwani, I 2016, 'Venous thromboembolism risk and adequacy of prophylaxis in high risk pregnancy in the Arabian Gulf', Current Vascular Pharmacology, vol. 14, no. 4, pp. 368-373.
Alsayegh, Faisal ; Al-Jassar, Waleed ; Wani, Salima ; Tahlak, Muna ; Al-Bahar, Awatef ; Al-Kharusi, Lamya ; Al-Tamimi, Halima ; El-Taher, Faten ; Mahmood, Naeema ; Al-Zakwani, Ibrahim. / Venous thromboembolism risk and adequacy of prophylaxis in high risk pregnancy in the Arabian Gulf. In: Current Vascular Pharmacology. 2016 ; Vol. 14, No. 4. pp. 368-373.
@article{39aaca32730942ada19c74bfc97dd0bd,
title = "Venous thromboembolism risk and adequacy of prophylaxis in high risk pregnancy in the Arabian Gulf",
abstract = "Objectives: To estimate the prevalence of venous thromboembolism (VTE) risk factors in pregnancy and the proportion of pregnancies at risk of VTE that received the recommended prophylaxis according to the American College of Chest Physicians (ACCP) 2012 published guidelines in antenatal clinics in the Arabian Gulf. Methods: The evaluation of venous thromboembolism (EVE)-Risk project was a non-interventional, cross-sectional, multi-centre, multi-national study of all eligible pregnant women (≥17 years) screened during antenatal clinics from 7 centres in the Arabian Gulf countries (United Arab Emirates, Kuwait, Bahrain, Qatar and Oman). Pregnant women were recruited during a 3-month period between September and December 2012. Results: Of 4,131 screened pregnant women, 32{\%} (n=1,337) had ≥1 risk factors for VTE. Common VTE risk factors included obesity (76{\%}), multiparity (33{\%}), recurrent miscarriages (9.1{\%}), varicose veins (6.9{\%}), thrombophilia (2.6{\%}), immobilization (2.0{\%}), sickle cell disease (2.8{\%}) and previous VTE (1.6{\%}). Only 8.3{\%} (n=111) of the high risk patients were on the recommended VTE prophylaxis. Enoxaparin was used in 80{\%} (n=89) of the cases followed by tinzaparin (4{\%}; n=4). Antiplatelet agents were prescribed in 11{\%} (n=149) of pregnant women. Of those on anticoagulants (n=111), 59{\%} (n=66) were also co-prescribed antiplatelet agents. Side effects (mainly local bruising at the injection site) were reported in 12{\%} (n=13) of the cases. Conclusion: A large proportion of pregnant women in the Arabian Gulf countries have ≥1 VTE risk factor with even a smaller fraction on prophylaxis. VTE risk assessment must be adopted to identify those at risk who would need VTE prophylaxis.",
keywords = "Anticoagulation, Antiplatelet, Deep vein thrombosis, Middle East, Pregnancy, Venous thromboembolism",
author = "Faisal Alsayegh and Waleed Al-Jassar and Salima Wani and Muna Tahlak and Awatef Al-Bahar and Lamya Al-Kharusi and Halima Al-Tamimi and Faten El-Taher and Naeema Mahmood and Ibrahim Al-Zakwani",
year = "2016",
month = "7",
day = "1",
language = "English",
volume = "14",
pages = "368--373",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Venous thromboembolism risk and adequacy of prophylaxis in high risk pregnancy in the Arabian Gulf

AU - Alsayegh, Faisal

AU - Al-Jassar, Waleed

AU - Wani, Salima

AU - Tahlak, Muna

AU - Al-Bahar, Awatef

AU - Al-Kharusi, Lamya

AU - Al-Tamimi, Halima

AU - El-Taher, Faten

AU - Mahmood, Naeema

AU - Al-Zakwani, Ibrahim

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Objectives: To estimate the prevalence of venous thromboembolism (VTE) risk factors in pregnancy and the proportion of pregnancies at risk of VTE that received the recommended prophylaxis according to the American College of Chest Physicians (ACCP) 2012 published guidelines in antenatal clinics in the Arabian Gulf. Methods: The evaluation of venous thromboembolism (EVE)-Risk project was a non-interventional, cross-sectional, multi-centre, multi-national study of all eligible pregnant women (≥17 years) screened during antenatal clinics from 7 centres in the Arabian Gulf countries (United Arab Emirates, Kuwait, Bahrain, Qatar and Oman). Pregnant women were recruited during a 3-month period between September and December 2012. Results: Of 4,131 screened pregnant women, 32% (n=1,337) had ≥1 risk factors for VTE. Common VTE risk factors included obesity (76%), multiparity (33%), recurrent miscarriages (9.1%), varicose veins (6.9%), thrombophilia (2.6%), immobilization (2.0%), sickle cell disease (2.8%) and previous VTE (1.6%). Only 8.3% (n=111) of the high risk patients were on the recommended VTE prophylaxis. Enoxaparin was used in 80% (n=89) of the cases followed by tinzaparin (4%; n=4). Antiplatelet agents were prescribed in 11% (n=149) of pregnant women. Of those on anticoagulants (n=111), 59% (n=66) were also co-prescribed antiplatelet agents. Side effects (mainly local bruising at the injection site) were reported in 12% (n=13) of the cases. Conclusion: A large proportion of pregnant women in the Arabian Gulf countries have ≥1 VTE risk factor with even a smaller fraction on prophylaxis. VTE risk assessment must be adopted to identify those at risk who would need VTE prophylaxis.

AB - Objectives: To estimate the prevalence of venous thromboembolism (VTE) risk factors in pregnancy and the proportion of pregnancies at risk of VTE that received the recommended prophylaxis according to the American College of Chest Physicians (ACCP) 2012 published guidelines in antenatal clinics in the Arabian Gulf. Methods: The evaluation of venous thromboembolism (EVE)-Risk project was a non-interventional, cross-sectional, multi-centre, multi-national study of all eligible pregnant women (≥17 years) screened during antenatal clinics from 7 centres in the Arabian Gulf countries (United Arab Emirates, Kuwait, Bahrain, Qatar and Oman). Pregnant women were recruited during a 3-month period between September and December 2012. Results: Of 4,131 screened pregnant women, 32% (n=1,337) had ≥1 risk factors for VTE. Common VTE risk factors included obesity (76%), multiparity (33%), recurrent miscarriages (9.1%), varicose veins (6.9%), thrombophilia (2.6%), immobilization (2.0%), sickle cell disease (2.8%) and previous VTE (1.6%). Only 8.3% (n=111) of the high risk patients were on the recommended VTE prophylaxis. Enoxaparin was used in 80% (n=89) of the cases followed by tinzaparin (4%; n=4). Antiplatelet agents were prescribed in 11% (n=149) of pregnant women. Of those on anticoagulants (n=111), 59% (n=66) were also co-prescribed antiplatelet agents. Side effects (mainly local bruising at the injection site) were reported in 12% (n=13) of the cases. Conclusion: A large proportion of pregnant women in the Arabian Gulf countries have ≥1 VTE risk factor with even a smaller fraction on prophylaxis. VTE risk assessment must be adopted to identify those at risk who would need VTE prophylaxis.

KW - Anticoagulation

KW - Antiplatelet

KW - Deep vein thrombosis

KW - Middle East

KW - Pregnancy

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84978225148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978225148&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 368

EP - 373

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 4

ER -